Erin Lanciani - Sage Therapeutic Vice President - Human Resources

SAGE Stock  USD 18.79  0.25  1.31%   

President

Ms. Erin Lanciani is Vice President Human Resources of the Company. Erin Lanciani brings more than 20 years of experience in developing human resources strategies and programs to the company. Before joining SAGE Ms. Lanciani served as executive director human resources global commercialization at BristolMyers Squibb joining the company through its October 2007 acquisition of Adnexus where she was the vice president of human resources and a member of the executive leadership team. In 2009 Erin relocated to Paris where she was the HR director for European markets at BMS and served as a strategic business partner responsible for all aspects of HR across multiple European commercial RD and corporate functions. Prior to BMS Ms. Lanciani was vice president of human resources at Therion Biologics and also served as the director of human resources for ViaCell as a human resources business partner at Genzyme Corporation and was a founderpartner of Outsourcing Solutions Inc. a human resources consulting firm. She earned her B.S. in business administration from Northeastern University. since 2015.
Age 55
Tenure 9 years
Address 215 First Street, Cambridge, MA, United States, 02142
Phone617 299 8380
Webhttps://www.sagerx.com

Sage Therapeutic Management Efficiency

The company has return on total asset (ROA) of (0.3051) % which means that it has lost $0.3051 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5277) %, meaning that it created substantial loss on money invested by shareholders. Sage Therapeutic's management efficiency ratios could be used to measure how well Sage Therapeutic manages its routine affairs as well as how well it operates its assets and liabilities. As of March 28, 2024, Return On Capital Employed is expected to decline to -0.76. In addition to that, Return On Assets is expected to decline to -0.64. At present, Sage Therapeutic's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 7.3 M, whereas Other Current Assets are forecasted to decline to about 20.8 M.
The company currently holds 5.17 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Sage Therapeutic has a current ratio of 17.34, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Sage Therapeutic until it has trouble settling it off, either with new capital or with free cash flow. So, Sage Therapeutic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sage Therapeutic sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sage to invest in growth at high rates of return. When we think about Sage Therapeutic's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 11 records

PRESIDENT Age

Alicia RodriguezAgilent Technologies
N/A
Dominique GrauAgilent Technologies
65
Rodney GonsalvesAgilent Technologies
58
Jacob ThaysenAgilent Technologies
49
Samraat RahaAgilent Technologies
51
Henrik AncherJensenAgilent Technologies
59
Michael TangAgilent Technologies
50
Mark DoakAgilent Technologies
63
Patrick KaltenbachAgilent Technologies
53
Robert McMahonAgilent Technologies
55
Eilon AsculaiMediwound
N/A
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Sage Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 471 people. Sage Therapeutic (SAGE) is traded on NASDAQ Exchange in USA. It is located in 215 First Street, Cambridge, MA, United States, 02142 and employs 487 people. Sage Therapeutic is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Sage Therapeutic Leadership Team

Elected by the shareholders, the Sage Therapeutic's board of directors comprises two types of representatives: Sage Therapeutic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sage. The board's role is to monitor Sage Therapeutic's management team and ensure that shareholders' interests are well served. Sage Therapeutic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sage Therapeutic's outside directors are responsible for providing unbiased perspectives on the board's policies.
Howard Pien, Independent Director
Christopher Benecchi, Chief Officer
Laura MD, Chief Officer
Kimi Iguchi, CFO
Erin Lanciani, Vice President - Human Resources
Anne Cook, Senior Vice President General Counsel, Secretary
Kimi CPA, CFO Treasurer
James Frates, Independent Director
Frank Sanders, Vice President of Sales and Marketing
Elizabeth Barrett, Director
Matt Lasmanis, Chief Officer
Jim Doherty, Chief Officer
Geno Germano, Director
Steven Paul, Independent Director
Thomas Anderson, Chief Commercial Strategy Officer
Albert Robichaud, Chief Scientific Officer
Michael Cloonan, Chief Business Officer
Anne Esq, General VP
Robert Nelsen, Independent Director
Ashley Kaplowitz, Director Relations
Kevin Starr, Independent Director
Amy Schacterle, Vice President - Regulatory Affairs and Quality Assurance
Asha Nayak, Director
Mike Quirk, Chief Officer
George Golumbeski, Director
Stephen Kanes, Chief Medical Officer
Jeffrey Jonas, President CEO, Director
Christopher Silber, Senior Vice President - Clinical Development
Barry Greene, CEO President
Paul Hodgkins, Vice President - Health Economics and Outcomes Research and Value Demonstration
Helen Rubinstein, Investor Officer
Michael Cola, Director

Sage Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sage Therapeutic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Sage Therapeutic is a strong investment it is important to analyze Sage Therapeutic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sage Therapeutic's future performance. For an informed investment choice regarding Sage Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.
Note that the Sage Therapeutic information on this page should be used as a complementary analysis to other Sage Therapeutic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Sage Stock analysis

When running Sage Therapeutic's price analysis, check to measure Sage Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sage Therapeutic is operating at the current time. Most of Sage Therapeutic's value examination focuses on studying past and present price action to predict the probability of Sage Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sage Therapeutic's price. Additionally, you may evaluate how the addition of Sage Therapeutic to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Is Sage Therapeutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(9.05)
Revenue Per Share
1.445
Quarterly Revenue Growth
26.215
Return On Assets
(0.31)
Return On Equity
(0.53)
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.